Hi-Risk/Recurrent/Advanced PCa Video Chat, June 14, 2022
Register for our upcoming webinar on June 29 on Genetics & Genomics at https://bit.ly/3QiNvxS
If you’re a Vet, AnCan will be launching a new Vets Group to help navigate medical care. First meeting Thu, June 23, at 8.00 pm Eastern in https://www.gotomeet.me/AnswerCancer. Free and drop-in as always!
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Editor’s Pick: Long term survival with metastatic PCa is this week’s recurring theme (rd)
Topics Discussed
Newbie joins us with Lynch Syndrome; anti-PD1 immuno side effects, MSI – and the swab test for sensitivity; darolutamide monotherapy; brain fog from HT; lung nodules ID’d as PCa; stable, long-trm survivor; supporting non-particpants; care partners extend survival; when’s the right time for Pluvicto?; BIG Pluvicto success
Chat Log
AnCan – rick (to Everyone): 3:09 PM: Peter – I spoke with Alexa today about saving the chat. Evidently it depends on how you join. She will provide an explanation and directions in all our future emails.
Jeff Marchi, San Francisco (to Everyone): 3:37 PM: free genetic test if you have prostate cancer. https://www.prostatecancerpromise.org
George Rovder Arlington VA (to Everyone): 3:41 PM: Thank you Jeff Marchi. I appreciate it and will check it out. George
Len Sierra (to Everyone): 3:49 PM: https://miradx.com/imudx-testing/ The Keytruda test: IMUDX swab test ImuDx Testing Populations Patients with any type of cancer who are being considered for anti-PD1 or anti-PDL1 therapy are eligible for testing. This test predicts the risk of developing immune related adverse events in response to anti-PD1 or anti-PDL1 treatment.
Herb Geller (to Everyone): 3:50 PM: Cardiac toxicity from checkpoing therapy can range from asymptomatic troponin-I elevations to conduction abnormalities of the heart and even fulminant myocarditis. Although rare, myocarditis is a potentially fatal adverse effect of ICI therapy.
George Rovder Arlington VA (to Everyone): 3:54 PM: Thank you all, friends, for the wisdom and kindness. I have to leave early this evening. I will watch the video to see and hear the rest of the discussion. George
AnCan – rick (to Everyone): 3:55 PM: Bill’s Genetics 101 Primer https://ancan.org/cancer-genetics-101-a-very-basic-primer/
Julian Morales – Houston (to Everyone): 3:58 PM: Have to leave, have a conflicting meeting at 6pm.
Ben Nathanson (to Everyone): 4:00 PM: @Richard – ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC) https://meetings.asco.org/abstracts-presentations/201628
Pat Martin (to Everyone): 4:00 PM: Thanks for the info and the links
George A Southiere Jr (to Everyone): 4:04 PM: very correct that most of us have been on multiple treatments that cause”brain fog”would be very difficult to discern. Be very skeptical of Pharmaceutical studies
John Antonucci (to Everyone): 4:08 PM: I just tried to find any paper on monotherapy androgen blockers and came up with zilch
Thomas Jacobsen – CO (to Everyone): 4:43 PM: Have to leave. Thank you everyone.
Russ Strehlow (to Everyone): 4:46 PM: I have to leave also. Thank you
George A Southiere Jr (to Everyone): 4:50 PM: Great meeting everyone, gotta go. Be well all
Richard Wassersug (to Everyone): 5:00 PM: Thank you all. Have to go.
Herb Geller (to Everyone): 5:00 PM: I gotta go as well. See you all next week.
David Muslin (to Everyone): 5:01 PM: Great meeting as always. See you men next Monday night.